Phase 3 ECHO: Safety Data Review

Pre-planned interim results from the phase EPCORE FL-1 trial supported the FDA granting priority review to epcoritamab with rituximab and lenalidomide in relapsed/refractory FL.

Advances in next-generation sequencing and gene expression are reshaping T-cell lymphoma classification and the use of targeted therapies.

Results from the marginal zone lymphoma cohort of the TRANSCEND FL trial showed liso-cel elicited an ORR of 95.5% and a CR rate of 62.1%.

Steven E. Finkelstein, MD, DABR, FACRO discuses how Prolaris distinguishes itself from other genomic biomarker platforms by providing uniquely actionable clinical information that quantifies the absolute benefit of androgen deprivation therapy when added to radiation therapy, offering clinicians a more precise tool for personalizing prostate cancer treatment strategies.

Results from the phase 3 TRIANGLE trial showed prolonged failure-free survival and overall survival with ibrutinib and CIT vs CIT plus ASCT alone.

In lieu of an 8-1 ODAC ruling against the applicability of the phase 3 STARGLO results in US patients, a CRL has been issued for glofitamab in relapsed/refractory DLBCL.